Payment overview · 2025
General Payments
$326.84
19 reported records · 6 companies
Healthcare provider profile · identity verified
Robert P Tully, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · MESA, AZ · NPI 1013932870
Verified facts
What the public records show
CMS Open Payments records show Robert P Tully, M.D. received $326.84 in general payments during 2025 across 19 reported records.
Amgen Inc. accounted for 51.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $167.80 | 51.3% | 12 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.47 | 18.8% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $28.11 | 8.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $26.25 | 8.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.60 | 7.2% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $19.61 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $326.84 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $103.77 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $103.77 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $64.03 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.47 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $28.11 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 473 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 289 | 88 |
| Losartan Potassium | Losartan Potassium | 233 | 69 |
| Gabapentin | Gabapentin | 203 | 57 |
| Metformin Hcl | Metformin Hcl | 170 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 57 |
| Meloxicam | Meloxicam | 165 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 52 |
| Sertraline Hcl | Sertraline Hcl | 163 | 55 |
| Furosemide | Furosemide | 157 | 50 |
| Lisinopril | Lisinopril | 151 | 46 |
| Celecoxib | Celecoxib | 149 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 43 |
| Omeprazole | Omeprazole | 121 | 37 |
| Potassium Chloride | Potassium Chloride | 121 | 32 |
| Eliquis | Apixaban | 116 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 110 | 33 |
| Bupropion Xl | Bupropion Hcl | 106 | 34 |
| Atenolol | Atenolol | 102 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 30 |
| Simvastatin | Simvastatin | 93 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 28 |
| Trazodone Hcl | Trazodone Hcl | 89 | 30 |
| Mirtazapine | Mirtazapine | 87 | 29 |
| Allopurinol | Allopurinol | 84 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 81 | 58 |
| Spironolactone | Spironolactone | 78 | 25 |
| Methylprednisolone | Methylprednisolone | 75 | 46 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 26 |
| Famotidine | Famotidine | 68 | 22 |
| Glimepiride | Glimepiride | 68 | 23 |
| Azithromycin | Azithromycin | 64 | 54 |
| Ezetimibe | Ezetimibe | 64 | 20 |
| Carvedilol | Carvedilol | 56 | 19 |
| Chlorthalidone | Chlorthalidone | 54 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 12 |
| Montelukast Sodium | Montelukast Sodium | 51 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 16 |
| Finasteride | Finasteride | 45 | 12 |
| Memantine Hcl | Memantine Hcl | 43 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 13 |
| Estradiol | Estradiol | 39 | 15 |
| Synthroid | Levothyroxine Sodium | 38 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 12 |
| Lorazepam | Lorazepam | 36 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 13 |
| Prednisone | Prednisone | 31 | 18 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 30 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | 13 |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | 12 |
| Naproxen | Naproxen | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Dexamethasone | Dexamethasone | 18 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | 12 |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $326.84 · 19 records | Amgen Inc. | Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, INJECTAFER, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Leqembi, OTEZLA, REPATHA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error